Arsanis Nets New Debt Financing
Monday, January 4, 2016 5:53:00 AM PDT | VentureDeal
   Waltham, Massachusetts  --  Biotechnology company Arsanis has landed $4 million in venture capital debt funding, according to an SEC filing.

Arsanis is developing fully human monoclonal antibodies that operate against severe infectious diseases.

Investors in the financing weren't disclosed in the filing.

A total of eight investors participated in the offering.

The company did not say how the funding proceeds would be used.